Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932643 · ClinicalTrials.gov registry record · Phase 1
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03932643 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 20 participants.
The verdict
NCT03932643, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single-center Phase 1 trial of 20 patients with AML/MDS. Eligible patients will be enrolled following an informed consent between 6-20 weeks after allogeneic hematopoietic stem cell transplant. Patients will receive weekly oral ONC 201 for a total of 52 weeks.
Interventions
- DRUG ONC-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03932643
The ClinicalTrials.gov registry entry for NCT03932643 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONC-201 is the first listed.
NCT03932643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03932643 about?
NCT03932643 is a clinical study titled "ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant". This is a single-center Phase 1 trial of 20 patients with AML/MDS. Eligible patients will be enrolled following an informed consent between 6-20 weeks after allogeneic hematopoietic stem cell transplant. Patients will receive weekly oral ONC 201 for a total of 52 weeks.
What is the current status of trial NCT03932643?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-07-30. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT03932643?
The interventions under investigation include: ONC-201 (DRUG).
Who is sponsoring clinical trial NCT03932643?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.